Kelsey Barrasso

Kelsey Barrasso

Auto-generated profile, based on publicly available information

Kelsey Barrasso

Seres Therapeutics , Cambridge, MA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2020 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
SWSamit Watve
Samit Watve
KBKelsey Barrasso
Kelsey Barrasso
SJSarah A Jung
Sarah A Jung
KDKristen J Davis
Kristen J Davis
LHLisa A Hawver
Lisa A Hawver
WNWai-Leung Ng
Wai-Leung Ng
Many bacteria use quorum sensing (QS) to regulate virulence factor production in response to changes in population density. QS is mediated through the production, secretion, and detection of signaling molecules called autoinducers (AIs) to modulate population-wide behavioral changes. Four histidine kinases, LuxPQ, CqsS, CqsR and VpsS, have been identified in Vibrio cholerae as QS receptors to activate virulence gene expression at low cell density. Detection of AIs by these receptors leads to virulence gene repression at high cell density. The redundancy among these receptors is puzzling since any one of the four receptors is sufficient to support colonization of V. cholerae in the host small intestine. It is believed that one of the functions of such circuit architecture is to prevent interference on any single QS receptor. However, it is unclear what natural molecules can interfere V. cholerae QS and in what environment interference is detrimental. We show here mutants expressing only CqsR without the other three QS receptors are defective in colonizing the host large intestine. We identified ethanolamine, a common intestinal metabolite that can function as a chemical source of QS interference. Ethanolamine specifically interacts with the ligand-binding CACHE domain of CqsR and induces a premature QS response in V. cholerae mutants expressing only CqsR without the other three QS receptors. The effect of ethanolamine on QS gene expression and host colonization is abolished by mutations that disrupt CqsR signal sensing. V. cholerae defective in producing ethanolamine is still proficient in QS, therefore, ethanolamine functions only as an external cue for CqsR. Our findings suggest the inhibitory effect of ethanolamine on CqsR could be a possible source of QS interference but is masked by the presence of the other parallel QS pathways, allowing V. cholerae to robustly colonize the host. Many pathogens use quorum sensing (QS) to regulate virulence gene expression for their survival and adaptation inside hosts. QS depends on the production and detection of chemical signals called autoinducers made endogenously by the bacteria. However, chemicals present in the surrounding environment could potentially lead to quorum signal interference, resulting in mis-regulation of virulence factor production and preventing effective host colonization. We show here ethanolamine, a metabolite commonly found inside the mammalian intestine, modulates the activity of one of the QS receptors in Vibrio cholerae, the etiological agent of the disease cholera. Despite the abundance of this common metabolite inside the host, by integrating multiple parallel signal inputs into its QS system, V. cholerae has evolved to maintain QS fidelity and avoids signal interference to allow robust colonization of the host.

29 October 2020 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
KBKelsey Barrasso
Kelsey Barrasso
SWSamit Watve
Samit Watve
CSChelsea Simpson
Chelsea Simpson
LGLogan Geyman
Logan Geyman
JKJulia Van Kessel
Julia Van Kessel
WNWai-Leung Ng
Wai-Leung Ng

27 November 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
EHElizabeth Halvorsen
Elizabeth Halvorsen
MVMarin Vulić
Marin Vulić
KBKelsey Barrasso
Kelsey Barrasso
NBNicholas Beauchemin
Nicholas Beauchemin
JBJessica Brown
Jessica Brown
MHMatthew Henn
Matthew Henn
In chronic liver disease (CLD), gut microbiome disruption worsens with disease severity and growing evidence suggests it is a key driver of infection risk through a combination of intestinal pathogen expansion from a loss of colonization resistance and dysfunction of the gastrointestinal (GI) barrier. For the SER-147 preclinical program, we evaluated rationally designed cultivated consortia of human commensal bacteria in vitro and in vivo for the ability to reduce the abundance of pathogens commonly observed in patients with CLD, such as Enterococcus and Enterobacteriaceae. Candidate consortia for SER-147 were designed by leveraging genomic data from public observational CLD patient studies and Seres interventional human trial data to include taxa associated with reduced risk of infection and select strains from Seres’ strain library to maximize features associated with decolonizing key pathogens. We developed a novel in vitro gut-ecology model (iGEM) system that propagates human stool-derived microbial communities to evaluate candidate consortia for their ability to reduce titers of vancomycin-resistant Enterococcus faecium (VRE), and both carbapenem-resistant Klebsiella pneumoniae (CR-Kpn) and Escherichia coli (CR-Ec). In vivo, candidate consortia were evaluated for their ability to reduce fecal titers of VRE and CR-Kpn in mouse models of gut pathogen colonization. Reduction in abundance of Cr-Kpn, Cr-Ec, and VRE after microbiome intervention in the iGEM system. Reduction in abundance of Cr-Kpn and VRE after microbiome intervention in mouse models of gut pathogen colonization. (A) Wild-type C57BL/6 mice underwent antibiotic conditioning prior to pathogen challenge. Following the introduction of pathogen (Day 0) mice were dosed daily vial oral gavage with five unique candidate consortia (DE061, DE456, DE240, DE714, and DE492) as the microbiome intervention or vehicle only for 6 days and fecal titers are monitored for a 3-week period to evaluate pathogen abundance (B,C) The titers of VRE or CR-Kpn were quantified in fecal pellets by plating on selective agar at the indicated time-points. The median (B) CR-Kpn and (C) VRE CFU per gram of feces was calculated for each group and plotted on the line graph (n=9 per group). L.O.D., limit of detection. Preclinical assessments in vitro and in vivo support the ability of SER-147 candidate consortia to reduce VRE, CR-Kpn, and CR-Ec abundance in the gut. These results support the potential ability of microbiome therapeutics to reduce the risk of infection in patients with CLD. Elizabeth Halvorsen, PhD, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Marin Vulić, PhD, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Kelsey Barrasso, PhD, Seres Therapeutics: Stocks/Bonds Nicholas Beauchemin, n/a, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Jessica Brown, n/a, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Nathaniel J. Ennis, n/a, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Melissa Mayol, n/a, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Jenna Wurster, PhD, Seres Therapeutics: Paid Employee|Seres Therapeutics: Stocks/Bonds Edward J. O'Brien, PhD, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Christopher Ford, PhD, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds Matthew Henn, PhD, Seres Therapeutics: Employee|Seres Therapeutics: Stocks/Bonds